전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved71 programs
AntibodyLimited DatastaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Recruiting
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleMyeloid TherapeuticsPhase 1

atezolizumab (Tecentriq, MT-303 +Atezolizumab + Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Myeloid
Trials 1Status Recruiting
CGTLimited DatastaleKAEDIPhase 1

NKG2D-based CAR T-cells (NKG2D-based CAR T-cells)

Hepatocellular Carcinoma; Glioblastoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×8 times (Normal Dose NK cells ×8 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#monoclonal-antibody#HepatocellularCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 2

PVE+cTACE+Camrelizumab+Apatinib (PVE+cTACE+Camrelizumab+Apatinib)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, PXS-5505 and Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma; Cancer of Liver · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#CancerofLiver+1
Trials 1Status Discontinued
CGTLimited DatastaleGuangzhou Virotech Pharmaceutic…Phase 1

Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib (Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib)

Advanced/Metastatic Hepatocellular Carcinoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#monoclonal-antibody#Carcinoma+3
Trials 1Status Active
CGTLimited DatastaleXinqiao Hospital of ChongqingPhase 2

Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs (Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleAbramson Cancer Center at Penn …Phase 1

atezolizumab (Tecentriq, SBRT + atezolizumab and bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Abramson
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Recruiting
CGTLimited DatastaleGuangdong ProCapZoom Bioscience…Preclinical

SZ003 CAR-NK (SZ003 CAR-NK)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#monoclonal-antibody#Innovent
Trials 1Status Active

3 / 4 pages

← PreviousNext →